Prevent Quality Failures Before They Happen
Operationalizing FDA’s QMM Vision for All Industries — at Scale
Regller helps manufacturers measure, improve, and sustain Quality Management Maturity (QMM) using FDA-aligned practice areas, auditable evidence, and executive dashboards — so quality becomes predictable, not reactive.
QMM is not an inspection — and not a one-time project.
FDA and industry discussions emphasize that Quality Maturity Model (QMM) is intended to evaluate the maturity of quality management practices at a site — distinct from a typical CGMP inspection — and is centered on how quality systems are designed, led, measured, and improved over time.
Regller View
Treat QMM as a continuous initiative. Standardization, Automation, Monitoring and Prediction of Risks can drive quality improvement. Regller Platform is designed to achieve this.
Regller QMM Software
Regller follows a structured, repeatable assessment process to establish quality maturity baselines and enable continuous improvement aligned with FDA QMM principles.
Each assessment is aligned with FDA Title 21 codes to ensure compliance requirements. QMM Scores are defined as QML – quality maturity level. QMM scoring is mapped to Title 21 expectations.
- QMM assessment score for each assessment
- Track assessment score improvements over time
- Every assessment creates two results — manual score and automated AI score
- Setup automated assessment to run at pre-defined schedule, saving audit time
- Maturity reflects capability to comply, not just outcomes
- Management review aligns with regulatory intent
How It Works
1. Scope and Alignment
Define assessment scope across sites, functions, and processes. Align assessment criteria to FDA QMM practice areas and Title 21 requirements.
2. Assessment
Structured questionnaire-based assessment covering all QMM practice areas. Dual scoring: manual expert evaluation plus automated AI-driven scoring.
3. Benchmarking
Compare maturity scores across sites, products, and peer groups. Identify performance gaps and prioritize improvement areas with data-driven insights.
4. Action Plan
Generate targeted improvement roadmaps based on assessment findings. Assign actions, set timelines, and track remediation progress in real-time.
5. Continuous Improvement
Schedule recurring assessments. Monitor maturity trends over time. Embed continuous improvement into your quality operating rhythm with automated monitoring.
The Five Levels of Quality Maturity
| Level | Name | Description |
|---|---|---|
| 1 | Reactive | Quality is managed through inspection and reaction to problems |
| 2 | Defined | Quality processes are documented but inconsistently followed |
| 3 | Managed | Quality processes are standardized and measured across the organization |
| 4 | Predictive | Data analytics enable proactive quality risk management |
| 5 | Continuously Improving | Quality culture drives systematic improvement and innovation |
Why Regller QMM
QMM Made Practical. Maturity Made Measurable.
Meet FDA Title 21 Requirements.
Title 21 Alignment
Documents, templates, and audit questions derived directly from FDA Title 21 requirements. Clear linkage between regulatory expectations, evidence, actions, and outcomes.
Risk-Based Prioritization
Automated identification of high-impact risks using leading indicators and trend analysis. Focus resources where they matter most.
FDA QMM Aligned
Structured assessment model aligned with publicly described FDA QMM practice areas. Objective, repeatable, and audit-ready.
Management Aligned
Full alignment with company management commitment. Executive dashboards and governance workflows supporting effective leadership oversight. Part 11 compliant solution.
Enterprise Visibility
Cross-site, cross-function visibility into quality status, trends, and maturity. Visibility amongst peer group for quality differentiation.
Color-Coded Dashboards
Quality maturity overview, risk heatmaps, trend analysis, management review dashboards, and improvement tracking — all in one place.
Why Leading Manufacturers Choose Regller for QMM
- Faster assessment cycles — Complete QMM assessments in weeks, not months
- Data-driven benchmarking — Compare against real industry data, not assumptions
- AI-powered recommendations — Prioritized improvement plans based on your specific gaps
- Regulatory alignment — Stay ahead of FDA expectations as the QMM program evolves
- Audit readiness — Demonstrate quality maturity improvement to FDA inspectors
FDA QMM
What is FDA QMM?
FDA’s Center for Drug Evaluation and Research (CDER) is establishing a Quality Management Maturity (QMM) program to encourage drug manufacturers to implement quality management practices that go beyond current good manufacturing practice (CGMP) requirements.
The QMM effort is designed to promote stronger quality management and a stronger quality culture, with the broader goal of improving reliability and reducing quality-related disruptions.
QMM shifts the conversation from “Are we compliant?” to:
- Are we consistently capable?
- Are we resilient under stress?
- Do we detect and prevent issues early?
FDA has described how QMM ratings could help stakeholders better understand site quality management practices and potentially inform decisions that impact supply reliability and oversight planning.
Supporting FDA’s Vision for Quality Maturity
FDA defines the vision for quality maturity. Regller provides the digital foundation to make that vision measurable, scalable, and actionable across the industry.
FDA Vision
Regller Solution
Strengthen manufacturing reliability to prevent drug shortages and protect patients.
Regller enables early identification of quality and maturity risks that historically lead to supply disruptions.
Shift from reactive oversight to predictable, performance-based quality outcomes.
Regller transforms quality from a subjective assessment into a measurable, repeatable maturity signal with standardized scoring.
Encourage sustained quality behaviors beyond point-in-time regulatory compliance.
Regller operationalizes continuous improvement by embedding QMM assessments into an ongoing digital lifecycle — assess, benchmark, improve, monitor.
Encourage quality as a strategic capability, not just a regulatory obligation.
Regller reframes quality as a strategic, data-driven capability by linking maturity scores to operational outcomes, risk signals, and improvement opportunities.
Frequently Asked Questions
Is QMM mandatory?
FDA has described QMM as a program and has operated voluntary prototype assessment protocol evaluation efforts.
Is QMM the same as a CGMP inspection?
Public discussions distinguish QMM assessments from typical inspections by focusing on maturity of quality management practices.
Does Regller provide an FDA rating?
No. Regller provides internal readiness scoring aligned to publicly described QMM practice areas to help you prepare and improve.
What sites should start first?
Start where the impact is highest: constrained products, high-volume sites, complex supply chains, or sites with recurring quality signals.
Be the Change